Abstract
The purpose of this study was to evaluate the effect of the new cardiotonic, imazodan (CI-914), on myocardial hemodynamics and oxygen consumption, and peripheral blood flow distribution. Organ blood flow was measured by the radiolabeled-microsphere-reference-withdrawal technique and myocardial oxygen consumption calculated from arterial and coronary sinus O2 content and blood flow. At inotropic levels, CI-914 decreases mean arterial pressure with a minimal increase in heart rate. CI-914 decreases coronary vascular resistance and increases supply to demand ratio, indicating an active coronary vasodilation. CI-914 does not alter peripheral blood flow distribution, thus suggesting equivalent organ vasodilation. These data suggest that CI-914 may be useful in the treatment of congestive heart failure because of its positive inotropic, coronary vasodilator, and peripheral vasodilator properties.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
